Research outputs
Selected research outputs
- SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study. (Journal article - 2023)
- Incidence of new onset type 2 diabetes in adults living with obesity treated with tirzepatide or semaglutide: real world evidence from an international retrospective cohort study. (Journal article - 2024)
- The rapidly increasing incidence of type 2 diabetes and macrovascular and microvascular complications disproportionately affects younger age groups: A decade of evidence from an international federated database (Journal article - 2025)
2026
Real-world evaluation of teplizumab in type 1 diabetes: Progression to insulin requirement
Mahesh, S., Anson, M., Malik, R. A., Cuthbertson, D. J., & Alam, U. (2026). Real-world evaluation of teplizumab in type 1 diabetes: Progression to insulin requirement. DIABETES OBESITY & METABOLISM, 28(3), 2425-2430. doi:10.1111/dom.70354
Synergistic associations of metformin and GLP-1 receptor agonist use with adiposity-related cancer incidence in people living with type 2 diabetes
Henney, A. E., Heague, M., Riley, D. R., Hydes, T. J., Anson, M., Alam, U., & Cuthbertson, D. J. (2026). Synergistic associations of metformin and GLP-1 receptor agonist use with adiposity-related cancer incidence in people living with type 2 diabetes. DIABETES OBESITY & METABOLISM, 28(2), 946-959. doi:10.1111/dom.70267
Relative efficacy of GLP-1 and GLP-1/GIP receptor agonists in the prevention of alcohol-use disorders using a target trial emulation approach
Henney, A. E., Riley, D. R., Heague, M., Roberts, C. A., Hydes, T. J., Anson, M., . . . Cuthbertson, D. J. (2026). Relative efficacy of GLP-1 and GLP-1/GIP receptor agonists in the prevention of alcohol-use disorders using a target trial emulation approach. DIABETES OBESITY & METABOLISM, 28(1), 137-150. doi:10.1111/dom.70169
2025
Spinal cord stimulation for the treatment of painful diabetic neuropathy and risk of major adverse cardiovascular events , mortality, amputation, infection and suicide: a retrospective cohort study
Henney, A. E., Frank, B., Riley, D. R., Anson, M., Burgess, J., Hernadez, G., . . . Alam, U. (2025). Spinal cord stimulation for the treatment of painful diabetic neuropathy and risk of major adverse cardiovascular events , mortality, amputation, infection and suicide: a retrospective cohort study. ECLINICALMEDICINE, 89. doi:10.1016/j.eclinm.2025.103489
Target Trial Emulations of GLP-1 and Dual GLP-1/GIP Agonists to Reduce Major Adverse Liver Outcomes in Type 2 Diabetes
Henney, A. E., Riley, D. R., Anson, M., Azmi, S., Alam, U., & Cuthbertson, D. J. (2025). Target Trial Emulations of GLP-1 and Dual GLP-1/GIP Agonists to Reduce Major Adverse Liver Outcomes in Type 2 Diabetes. LIVER INTERNATIONAL, 45(10). doi:10.1111/liv.70367
The rapidly increasing incidence of type 2 diabetes and macrovascular and microvascular complications disproportionately affects younger age groups: A decade of evidence from an international federated database
Anson, M., Henney, A. E., Edwards, H., Ibarburu, G. H., Mordi, I., Jaffar, S., . . . Alam, U. (2025). The rapidly increasing incidence of type 2 diabetes and macrovascular and microvascular complications disproportionately affects younger age groups: A decade of evidence from an international federated database. DIABETES RESEARCH AND CLINICAL PRACTICE, 228. doi:10.1016/j.diabres.2025.112431
The impact of insulin pump therapy compared to multiple daily injections on complications and mortality in type 1 diabetes: A real-world retrospective cohort study
Haughton, S., Riley, D., Berry, S., Arshad, M. F., Eleftheriadou, A., Anson, M., . . . Iqbal, A. (2025). The impact of insulin pump therapy compared to multiple daily injections on complications and mortality in type 1 diabetes: A real-world retrospective cohort study. DIABETES OBESITY & METABOLISM, 27(8), 4239-4247. doi:10.1111/dom.16455
Comparative Efficacy of Tirzepatide, Liraglutide, and Semaglutide in Reduction of Risk of Major Adverse Cardiovascular Events in Patients with Obstructive Sleep Apnea and Type 2 Diabetes Real-World Evidence
Henney, A. E., Riley, D. R., Anson, M., Heague, M., Hernadez, G., Alam, U., . . . Cuthbertson, D. J. (2025). Comparative Efficacy of Tirzepatide, Liraglutide, and Semaglutide in Reduction of Risk of Major Adverse Cardiovascular Events in Patients with Obstructive Sleep Apnea and Type 2 Diabetes Real-World Evidence. ANNALS OF THE AMERICAN THORACIC SOCIETY, 22(7), 1042-1052. doi:10.1513/AnnalsATS.202409-923OC
Type 2 Diabetes and associated Complications: Too little, too late?
Anson, M. (2025). Type 2 Diabetes and associated Complications: Too little, too late?. (University of Liverpool).
The cumulative impact of type 2 diabetes and obstructive sleep apnoea on cardiovascular, liver, diabetes-related and cancer outcomes
Riley, D. R., Henney, A., Anson, M., Hernadez, G., Zhao, S. S., Alam, U., . . . Cuthbertson, D. J. (2025). The cumulative impact of type 2 diabetes and obstructive sleep apnoea on cardiovascular, liver, diabetes-related and cancer outcomes. DIABETES OBESITY & METABOLISM, 27(2), 663-674. doi:10.1111/dom.16059
A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX
Ludwig, R. J., Anson, M., Zirpel, H., Thaci, D., Olbrich, H., Bieber, K., . . . Alam, U. (2025). A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX. FRONTIERS IN PHARMACOLOGY, 16. doi:10.3389/fphar.2025.1516126
2024
Comparative estimate of glucose-lowering therapies on risk of incident pneumonia and severe sepsis: an analysis of real-world cohort data.
Henney, A. E., Riley, D. R., Hydes, T. J., Anson, M., Ibarburu, G. H., Frost, F., . . . Cuthbertson, D. J. (2024). Comparative estimate of glucose-lowering therapies on risk of incident pneumonia and severe sepsis: an analysis of real-world cohort data.. Thorax. doi:10.1136/thorax-2024-221906
Small fibre pathology, small fibre symptoms and pain in fibromyalgia syndrome
Marshall, A., Rapteas, L., Burgess, J., Riley, D., Anson, M., Matsumoto, K., . . . Alam, U. (2024). Small fibre pathology, small fibre symptoms and pain in fibromyalgia syndrome. Scientific Reports, 14(1). doi:10.1038/s41598-024-54365-6
The chemoprotective effect of anti-platelet agents on cancer incidence in people with non-alcoholic fatty liver disease (NAFLD): a retrospective cohort study
Anson, M., Poon, J. S., Henney, A. E., Riley, D., Ibarbaru, G. H., Sieberhagen, C., . . . Hydes, T. (2024). The chemoprotective effect of anti-platelet agents on cancer incidence in people with non-alcoholic fatty liver disease (NAFLD): a retrospective cohort study. BMC MEDICINE, 22(1). doi:10.1186/s12916-024-03802-4
Metabolic syndrome traits differentially and cumulatively influence micro- and macrovascular disease risk in patients with MASLD.
Henney, A. E., Riley, D. R., Hydes, T. J., Anson, M., Ibarburu, G. H., Zhao, S. S., . . . Alam, U. (2024). Metabolic syndrome traits differentially and cumulatively influence micro- and macrovascular disease risk in patients with MASLD.. Liver international : official journal of the International Association for the Study of the Liver. doi:10.1111/liv.16086
Sodium-glucose cotransporter 2 inhibitors reduce the risk of incident type 2 diabetes in people with heart failure without diabetes: An analysis of real-world, cohort data.
Henney, A. E., Riley, D. R., Heague, M., Hydes, T. J., Anson, M., Alam, U., & Cuthbertson, D. J. (2024). Sodium-glucose cotransporter 2 inhibitors reduce the risk of incident type 2 diabetes in people with heart failure without diabetes: An analysis of real-world, cohort data.. Diabetes, obesity & metabolism, 26(10), 4665-4673. doi:10.1111/dom.15833
The chemoprotective effect of anti-platelet agents on obesity-related cancer incidence in people with metabolic dysfunction associated steatotic liver disease
Anson, M., Poon, J. S., Henney, A., Riley, D., Ibarbaru, G., Sieberhagen, C., . . . Hydes, T. (2024). The chemoprotective effect of anti-platelet agents on obesity-related cancer incidence in people with metabolic dysfunction associated steatotic liver disease. In GUT Vol. 73 (pp. A11-A12). doi:10.1136/gutjnl-2024-BASL.14
Aspirin and Ticagrelor Versus Aspirin and Clopidogrel or Prasugrel and the Effect on Staphylococcal-associated Infections: A Real-world Study
Essa, H., Ding, W. Y., Rana, F., Zhao, S. S., Anson, M., Austin, P., . . . Alam, U. (2024). Aspirin and Ticagrelor Versus Aspirin and Clopidogrel or Prasugrel and the Effect on Staphylococcal-associated Infections: A Real-world Study. CLINICAL THERAPEUTICS, 46(9), 689-695. doi:10.1016/j.clinthera.2024.07.001
Incidence of new onset type 2 diabetes in adults living with obesity treated with tirzepatide or semaglutide: real world evidence from an international retrospective cohort study.
Anson, M., Henney, A. E., Broadwell, N., Zhao, S. S., Ibarburu, G. H., Lip, G. Y. H., . . . Alam, U. (2024). Incidence of new onset type 2 diabetes in adults living with obesity treated with tirzepatide or semaglutide: real world evidence from an international retrospective cohort study.. EClinicalMedicine, 75, 102777. doi:10.1016/j.eclinm.2024.102777
SGLT2 Inhibitors, but Not GLP-1 Receptor Agonists, Reduce Incidence of Gout in People Living With Type 2 Diabetes Across the Therapeutic Spectrum
Preston, F. G., Anson, M., Riley, D. R., Ibarburu, G. H., Henney, A., Lip, G. Y. H., . . . Zhao, S. S. (2024). SGLT2 Inhibitors, but Not GLP-1 Receptor Agonists, Reduce Incidence of Gout in People Living With Type 2 Diabetes Across the Therapeutic Spectrum. Clinical Therapeutics. doi:10.1016/j.clinthera.2024.06.021
Effect of combination pioglitazone with sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists on outcomes in type 2 diabetes: A systematic review, meta-analysis, and real-world study from an international federated database
Anson, M., Henney, A. E., Zhao, S. S., Ibarburu, G. H., Lip, G. Y. H., Cuthbertson, D. J., . . . Alam, U. (2024). Effect of combination pioglitazone with sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists on outcomes in type 2 diabetes: A systematic review, meta-analysis, and real-world study from an international federated database. DIABETES OBESITY & METABOLISM, 26(7), 2606-2623. doi:10.1111/dom.15576
Denosumab, for osteoporosis, reduces the incidence of type 2 diabetes, risk of foot ulceration and all-cause mortality in adults, compared with bisphosphonates: An analysis of real-world, cohort data, with a systematic review and meta-analysis.
Henney, A. E., Riley, D. R., O'Connor, B., Hydes, T. J., Anson, M., Zhao, S. S., . . . Cuthbertson, D. J. (2024). Denosumab, for osteoporosis, reduces the incidence of type 2 diabetes, risk of foot ulceration and all-cause mortality in adults, compared with bisphosphonates: An analysis of real-world, cohort data, with a systematic review and meta-analysis.. Diabetes, obesity & metabolism. doi:10.1111/dom.15708
Treating Type 2 Diabetes With Early, Intensive, Multimodal Pharmacotherapy: Real-World Evidence From an International Collaborative Database.
Anson, M., Malik, A., Zhao, S. S., Austin, P., Ibarburu, G. H., Jaffar, S., . . . Alam, U. (2024). Treating Type 2 Diabetes With Early, Intensive, Multimodal Pharmacotherapy: Real-World Evidence From an International Collaborative Database.. Journal of diabetes research, 2024, 3470654. doi:10.1155/2024/3470654
Cardiovascular Outcomes with Intravitreal Anti-Vascular Endothelial Growth Factor Therapy in Patients with Diabetes: A Real-World Data Analysis
Lai, J. Y. M., Riley, D. R., Anson, M., Henney, A., Cuthbertson, D. J., Hernadez, G., . . . Alam, U. (2024). Cardiovascular Outcomes with Intravitreal Anti-Vascular Endothelial Growth Factor Therapy in Patients with Diabetes: A Real-World Data Analysis. DIABETES THERAPY, 15(4), 833-842. doi:10.1007/s13300-024-01544-3
2023
Metformin and SGLT2i as First-line Combination Therapy in Type 2 Diabetes: A Real-world Study With a Focus on Ethnicity
Anson, M., Zhao, S. S., Essa, H., Austin, P., Ibarburu, G. H., Lip, G. Y. H., & Alam, U. (2023). Metformin and SGLT2i as First-line Combination Therapy in Type 2 Diabetes: A Real-world Study With a Focus on Ethnicity. CLINICAL THERAPEUTICS, 45(12), 1259-1265. doi:10.1016/j.clinthera.2023.07.026
Corneal Confocal Microscopy Predicts Cardiovascular and Cerebrovascular Events and Demonstrates Greater Peripheral Neuropathy in Patients with Type 1 Diabetes and Foot Ulcers
Lim, J. Z. M., Burgess, J., Ooi, C., Ferdousi, M., Azmi, S., Kalteniece, A., . . . Alam, U. (2023). Corneal Confocal Microscopy Predicts Cardiovascular and Cerebrovascular Events and Demonstrates Greater Peripheral Neuropathy in Patients with Type 1 Diabetes and Foot Ulcers. DIAGNOSTICS, 13(17). doi:10.3390/diagnostics13172793
SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study.
Anson, M., Zhao, S. S., Austin, P., Ibarburu, G. H., Malik, R. A., & Alam, U. (2023). SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study.. Diabetologia. doi:10.1007/s00125-023-05975-8
2022
Artificial Intelligence and Corneal Confocal Microscopy: The Start of a Beautiful Relationship
Alam, U., Anson, M., Meng, Y., Preston, F., Kirthi, V., Jackson, T. L., . . . Petropoulos, I. N. (2022). Artificial Intelligence and Corneal Confocal Microscopy: The Start of a Beautiful Relationship. JOURNAL OF CLINICAL MEDICINE, 11(20). doi:10.3390/jcm11206199
2020
Neurological Manifestations of COVID-19: A systematic review and current update
Whittaker, A., Anson, M., & Harky, A. (2020). Neurological Manifestations of COVID-19: A systematic review and current update. ACTA NEUROLOGICA SCANDINAVICA, 142(1), 14-22. doi:10.1111/ane.13266